Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105)

Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bortezomib / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Humans
  • Melphalan / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Prednisolone / therapeutic use
  • Randomized Controlled Trials as Topic

Substances

  • Bortezomib
  • Prednisolone
  • Melphalan